Share on StockTwits

Alkermes PLC (NASDAQ:ALKS) set a new 52-week high during trading on Wednesday, Analyst Ratings reports. The stock traded as high as $43.20 and last traded at $42.84, with a volume of 1,020,732 shares. The stock had previously closed at $40.46.

A number of research firms have recently commented on ALKS. Analysts at Leerink Swann raised their price target on shares of Alkermes PLC from $42.00 to $46.00 in a research note to investors on Monday, December 16th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes PLC in a research note to investors on Monday, December 16th. They now have a $41.00 price target on the stock. Finally, analysts at UBS AG downgraded shares of Alkermes PLC to a “neutral” rating in a research note to investors on Friday, December 6th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the company. Alkermes PLC currently has an average rating of “Hold” and a consensus target price of $34.38.

Alkermes PLC has a 1-year low of $19.77 and a 1-year high of $41.47. The stock has a 50-day moving average of $39.93 and a 200-day moving average of $34.66. The company has a market cap of $5.855 billion and a P/E ratio of 295.33.

Alkermes PLC (NASDAQ:ALKS) last announced its earnings results on Thursday, October 31st. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22. The company had revenue of $139.80 million for the quarter, compared to the consensus estimate of $137.35 million. During the same quarter in the previous year, the company posted $0.17 earnings per share. The company’s revenue for the quarter was up 12.7% on a year-over-year basis.

Alkermes plc., formerly Alkermes, Inc, is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.